Vargas-Partida Tonatiuh, Hernández-Cruz Manuel, Ruiz-Eng Rafael, Montiel-Jarquín Álvaro José, Vázquez-Cruz Eduardo, López-Colombo Aurelio
Instituto Mexicano del Seguro Social, Centro Médico Nacional "General de División Manuel Ávila Camacho", Hospital de Especialidades, Puebla. México.
Instituto Mexicano del Seguro Social, Delegación Estatal Puebla, Puebla. México.
Gac Med Mex. 2019;155(4):386-390. doi: 10.24875/GMM.19005227.
The assessment of lymphoma response to treatment is based on imaging studies.
To correlate the assessment of lymphoma treatment response by computed tomography (CT) and by positron emission tomography/computed tomography (PET/CT).
Cross-sectional, observational study, where records of patients with lymphoma under surveillance by CT and PET/CT were reviewed.
The study population consisted of 43 patients with a mean age of 32.7 ± 22.4 years; 26 (60.5 %) had a diagnosis of Hodgkin's lymphoma and 17 (9.5 %) had non-Hodgkin lymphoma. By CT, 34 (79.1 %) were diagnosed with disease and nine (20.9 %) without disease. The criteria used to assess the response was radiologist experience in 39 (90.7 %) and RECIST 1.1 criteria in four (9.3 %). The diagnosis by 18-FDG PET/CT was no response to treatment or partial response-recurrence in 32 (74.4 %) and response to treatment in 11 (25.6 %); with PERCIST criteria in 13 (30.2 %) and Deuaville criteria in 30 (69.8 %). When the diagnosis by CT versus 18-FDG PET/CT was compared, out of 11 patients with complete response on PET/CT, three had a similar CT diagnosis. Of the 34 patients with data consistent disease diagnosed by CT, 26 had similar results by 18-FDG PET/CT (p = 0.54).
The value of lymphoma treatment response on CT does not agree with that obtained by 18-FDG PET/CT.
淋巴瘤治疗反应的评估基于影像学研究。
对比计算机断层扫描（CT）和正电子发射断层扫描/计算机断层扫描（PET/CT）对淋巴瘤治疗反应的评估。
横断面观察性研究，回顾了接受CT和PET/CT监测的淋巴瘤患者记录。
研究人群包括43例患者，平均年龄32.7±22.4岁；26例（60.5%）诊断为霍奇金淋巴瘤，17例（9.5%）为非霍奇金淋巴瘤。通过CT检查，34例（79.1%）被诊断为疾病存在，9例（20.9%）为无疾病。用于评估反应的标准中，39例（90.7%）依据放射科医生经验，4例（9.3%）依据RECIST 1.1标准。18-FDG PET/CT诊断为治疗无反应或部分反应-复发的有32例（74.4%），治疗有反应的有11例（25.6%）；其中依据PERCIST标准的有13例（30.2%），依据Deauville标准的有30例（69.8%）。当比较CT与18-FDG PET/CT的诊断结果时，在PET/CT上有完全反应的11例患者中，3例CT诊断结果相似。在CT诊断为疾病存在且数据一致的34例患者中，26例18-FDG PET/CT结果相似（p = 0.54）。
CT对淋巴瘤治疗反应的评估价值与18-FDG PET/CT的评估结果不一致。
